secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001193125-25-047351
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves ARS Pharma's neffy 1 mg for pediatric allergic reactions
---------------------------------------------------------------------

- FDA approved neffy 1 mg (epinephrine nasal spray) on March 5, 2025 for children aged 4+ weighing 15-30 kg.
- Approval based on trials showing PK/PD consistent with injectable epinephrine; adverse events mild/transient.
- neffy 1 mg expected to be available in the U.S. by end of May 2025.
- Follows prior FDA approval of neffy 2 mg (Aug 2024) for patients ≥30 kg and EU approval (Aug 2024).
- Human factors studies show children as young as 10 and untrained individuals can administer effectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525047351/0001193125-25-047351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525047351/d831088d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-047351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer